Piramal Pharma Limited announced its financial results for the second quarter and half year ended September 30, 2026. The company reported a strong performance with a 28% year-over-year increase in revenue for Q2FY27, reaching ₹2,617 crore. EBITDA saw a substantial 72% jump to ₹385 crore. For the half year, revenue grew 23% to ₹4,887 crore, and EBITDA also increased by 72% to ₹669 crore. The company also raised its FY27 outlook, anticipating 19-20% revenue growth.
Piramal Pharma Reports Strong Q2 and H1 FY27 Financials
Piramal Pharma Limited has announced robust financial results for the second quarter (Q2FY27) and the first half (H1FY27) of the fiscal year, ending September 30, 2026. The company demonstrated significant year-over-year growth across key financial metrics, driven by strong performance in its various business segments.
Consolidated Financial Highlights
Q2 FY27 Performance:
- Revenue from Operations: Increased by 28% YoY to ₹2,617 crore (Q2 FY26: ₹2,044 crore).
- EBITDA: Grew by 72% YoY to ₹385 crore (Q2 FY26: ₹224 crore).
- EBITDA Margin: Expanded to 14.7% (Q2 FY26: 11.0%).
- PAT: Reported at ₹5 crore, a 105% increase from ₹(99) crore in Q2 FY26.
H1 FY27 Performance:
- Revenue from Operations: Increased by 23% YoY to ₹4,887 crore (H1 FY26: ₹3,977 crore).
- EBITDA: Grew by 72% YoY to ₹669 crore (H1 FY26: ₹389 crore).
- EBITDA Margin: Expanded to 13.7% (H1 FY26: 9.8%).
- PAT: Reported at ₹(64) crore, a 64% improvement from ₹(181) crore in H1 FY26.
Key Business Performance
Contract Development and Manufacturing Organization (CDMO)
- CDMO revenue saw a 36% YoY growth in Q2 FY27 and 28% YoY growth in H1 FY27.
- The segment benefited from strong RFP activity, order inflows, and improved execution.
Complex Hospital Generics (CHG)
- CHG revenue grew by 32% YoY in Q2 FY27 and 24% YoY in H1 FY27.
- Key drivers include sustained US market leadership in Inhalation Anesthesia and the integration of Kenalog®.
Piramal Consumer Healthcare (PCH)
- PCH revenue increased by 13% YoY in Q2 FY27 and 14% YoY in H1 FY27.
- Strong performance from Power Brands and e-commerce contributed to the growth.
FY27 Outlook Upgrade
Based on the strong first-half performance and continued business momentum, Piramal Pharma has upgraded its FY27 outlook. The company now anticipates revenue growth of 19% to 20% with meaningfully higher profitability for the full fiscal year.
Investor Information
Piramal Pharma Limited will be hosting a conference call on October 28, 2026, to discuss these results. Dial-in details have been provided for investors and analysts.
Source: BSE
